Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,231.45
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹94.69B
Enterprise Value₹117.93B
Total Cash (Recent Filing)₹2.27B
Total Debt (Recent Filing)₹18.44B
Price to Earnings (P/E)17.3
Beta0.85
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)43.13
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)71.07
Revenue Forecast (FY)₹57.61B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe company shifted from losses to sustained profitability in 2025–2026, with materially improved gross and net margins. This strengthens core earnings power, supports reinvestment and commercial scale, and reduces execution risk over the medium term if margins hold.
Improved Leverage And ROEMaterial deleveraging and an ROE recovery to ~18% improve financial flexibility and reduce interest burden. A stronger capital structure enables targeted capex, regulatory investments and potential M&A, enhancing resilience across business cycles over the coming months.
Steady Revenue Growth And Positive OCFConsistent top-line growth combined with positive operating cash flow shows the underlying businesses generate cash from operations. Even with FCF noise, stable revenue and operating cash provide a durable base to fund operations and selective investments.
Bears Say
Weak Free-cash-flow ConversionSharp FCF decline and low cash conversion versus earnings reduce the company's ability to self-fund growth, pay down debt or sustain distributions. Volatile FCF raises refinancing and capital-allocation risk, constraining strategic optionality over 2–6 months.
Historic Profitability VolatilityA recent profit recovery follows multi-year losses and uneven margins, highlighting execution and cycle vulnerability. The history of swings implies that sustained operational discipline and stable product flows are required for the turnaround to be durable.
Absolute Debt Remains MeaningfulAlthough leverage ratios improved, material outstanding debt still limits optionality and raises sensitivity to interest or revenue shocks. Further deleveraging is needed to reach best-in-class resilience and reduce pressure on cash flow during downturns.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹94.69B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 60 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on May 18, 2026. The company reported ₹13.77 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.77.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹13.77 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.316%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―